1. Induction chemotherapy in head and neck cancer
- Author
-
Yoann Pointreau, Gilles Calais, Jérôme Fayette, Ibrahim Atean, Jean-Louis Lefebvre, Cambefort, Jeanne, Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011] (GICC UMR 6239 CNRS), Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), Centre Léon Bérard [Lyon], Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, Université Lille Nord de France (COMUE)-UNICANCER, and Université de Tours-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Antineoplastic Agents ,Disease ,Targeted therapy ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Stage (cooking) ,induction chemotherapy ,Neoplasm Staging ,Pharmacology ,Chemotherapy ,Performance status ,business.industry ,Head and neck cancer ,Induction chemotherapy ,Prognosis ,medicine.disease ,Combined Modality Therapy ,Neoadjuvant Therapy ,taxanes ,Radiation therapy ,Chemotherapy, Adjuvant ,Head and Neck Neoplasms ,[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Carcinoma, Squamous Cell ,head and neck cancer ,organ preservation ,business - Abstract
International audience; Five hundred and fifty thousand new head and neck cancer cases are diagnosed each year worldwide. They are mostly locally advanced squamous cell carcinoma with a poor prognosis in terms of locoregional and distant failure. A major challenge for patients with locally advanced squamous cell carcinoma is to achieve a high cure rate while preserving functions. Treatment strategies are designed according to the disease stage, primary site, operable status, patient age, and performance status. Surgery, radiation therapy, chemotherapy, and more recently molecular-targeted therapies are part of these strategies, but their sequence remains to be defined. Over the last 30 years, induction chemotherapy has attained an important position in the management of patients with locally advanced squamous cell carcinoma, particularly since the introduction of taxanes. The decision to deliver induction chemotherapy (and its intensification) must be considered in the light of other treatments aiming at better locoregional control (normofractioned radiotherapy, accelerated or hyperfractionated radiotherapy, addition of concurrent chemotherapy, or of targeted therapy) with or without adjuvant treatment. This review summarizes the rationale, these data, and perspectives on induction chemotherapy-based strategies. Anti-Cancer Drugs 22: 613-620 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
- Published
- 2011